Publication | Closed Access

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer

Epithelial Ovarian CancerMedicinePharmacologyGynecologyPharmacotherapyCytotoxic Immunoconjugate Cmb-401Anti-cancer AgentCancer TreatmentOncologyRadiation OncologyOvarian Cancer